“in the event that there be overlap between the factual underpinning of the Claimant’s claim for relief in this matter and the underlying allegations in [the Petition Claim] the High Court be invited to re-visit the issue of whether these proceedings be transferred to the High Court to be case managed and tried together with that case”
“[The Petitioner] has already succeeded at trial in the County Court as to the existence of the Agreement, which means that, in equity, since April 2018 he has been an equal shareholder of [the Company]. As I mentioned, [R1] made [P] a 50% shareholder in [the Company] with effect from1 April 2018 . She admits, nonetheless, that she has treated [the Company] as if she has been the sole shareholder: she unilaterally decided to only pay to herself substantial dividends, to use over£116,000 of [the Company’s] monies to pay her own legal fees, and paid over to herself [the Company’s] alleged net profit of£252,054 . It is also evident to me that [R1] has diverted the entirety of [the Company’s] business to Biotech: she failed to renew [the Company’s] ability to trade, which was confirmed by the Medicines and Healthcare products Regulatory Agency on12 April 2022 (the same day [R1] spent£68,000 on a Mercedes motor vehicle). Her evidence is that Biotech was trading in the period February 2022 to December 2022, although she says Biotech did not commence trading as a pharmacy until sometime in 2023. Moreover, it is evident to me (particularly from the bank account statements referred to during Mr Roseman’s submissions, and from her own admissions during the appeal of her sentence for contempt) that Biotech continued dealing with Dermamed’s suppliers and clients. [R1] has failed to give any explanation as to what business activities Biotech was carrying out prior to it, allegedly, providing pharmacy services in 2023.”